Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

On Tuesday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) shared topline 12-week results from its FALCON Phase 2 trial of TERN-601.TERN stock is struggling to find support. Check the fundamentals hereThe therapy is an oral GLP-1 receptor agonist (GLP-1RA) as a potential treatment for obesity in adults without diabetes.Also Read: Eli Lilly’s Rare Weight Loss Data Miss Could Benefit CompetitorsWeight LossAt a 250 mg dose, placebo-adjusted weight loss was 1.8%, which was not statistically significant with p=0.056.A ...